Connect with us

Health

H.H.S. Scraps Studies of Vaccines and Treatments for Future Pandemics

Published

on

H.H.S. Scraps Studies of Vaccines and Treatments for Future Pandemics

The Trump administration has canceled funding for dozens of studies seeking new vaccines and treatments for Covid-19 and other pathogens that may cause future pandemics.

The government’s rationale is that the Covid pandemic has ended, which “provides cause to terminate Covid-related grant funds,” according to an internal N.I.H. document viewed by The New York Times.

But the research was not just about Covid. Nine of the terminated awards funded centers conducting research on antiviral drugs to combat so-called priority pathogens that could give rise to entirely new pandemics.

“This includes the antiviral projects designed to cover a wide range of families that could cause outbreaks or pandemics,” said one senior N.I.H. official who spoke on condition of anonymity for fear of retaliation.

The vaccine research also was not focused on Covid, but rather on other coronaviruses that one day might jump from animals to humans.

Advertisement

Describing all the research as Covid-related is “a complete inaccuracy and simply a way to defund infectious disease research,” the official said. Robert F. Kennedy Jr., the health secretary, has said that the N.I.H. is too focused on infectious diseases, the official noted.

The funding halts were first reported by Science and Nature. The cancellations stunned scientists who had depended on the government’s support.

“The idea that we don’t need further research to learn how to treat health problems caused by coronaviruses and prevent future pandemics because ‘Covid-19 is over’ is absurd,” said Pamela Bjorkman, a structural biologist at Caltech who had been studying new vaccines.

The goal of the projects was to have vaccines and drugs ready if a new pandemic hit, rather than spending precious months developing them from scratch.

“In the last pandemic, we really were caught with our pants down,” said Paul Bieniasz, a virologist at Rockefeller University who was collaborating with Dr. Bjorkman.

Advertisement

“And if we don’t learn that lesson and prepare better for the next pandemic, we are unlikely to do better than we did last time.”

Dr. Bieniasz, Dr. Bjorkman and their colleagues were developing a vaccine that might protect against a wide range of coronavirus species.

The researchers discovered new strategies to coax the immune system to learn how to recognize molecular features common to more than just one type of virus. Results from animal experiments were promising.

But now, with their funds abruptly cut, the scientists said they doubted they could build on those results. Dr. Bieniasz said that the termination had left him “angry, disappointed, frustrated.”

Other scientists had been working on antiviral treatments, part of a program started in 2021.

Advertisement

With $577 million in support from the N.I.H., a nationwide network of labs had been studying how viruses replicate, and then searching for drugs that could block them.

The researchers focused on viral families that include some of the most worrisome pathogens known, such as Ebola and Nipah virus. Scientists had discovered a number of promising molecules and were advancing toward clinical trials.

Reuben Harris, a molecular virologist at UT Health San Antonio, said that the promising compounds uncovered by the program included an antiviral drug that stops Ebola and related viruses from entering cells.

“It could be deployed to help a lot of people fast,” Dr. Harris said.

It looked as if some compounds might work against a number of virus families. “It’s some of the most exciting science I’ve seen in my career,” said Nevan Krogan, a systems biologist at the University of California, San Francisco.

Advertisement

On Wednesday morning, Dr. Krogan and dozens of his colleagues gathered in a campus meeting room to review those results. And they also discussed what, if anything, they could do now.

“One student asked me, ‘Well, I have an experiment booked on this microscope tomorrow — can I do it?’” Dr. Krogan said. “And I’m like, ‘Well, I don’t know.’”

Dr. Harris said that, without ongoing support, the promising drugs he and others had found would not move into clinical trials. “It’s tragic — I don’t have too many words to describe that right now,” he said.

In 2023, Mr. Kennedy said that he wanted to take “a break” from infectious disease research to focus instead on chronic disease.

Jason McLellan, a virologist at the University of Texas at Austin who worked on the antiviral program, saw the cancellations of pandemic research as following through on that promise.

Advertisement

Dr. McLellan, whose earlier research was fundamental to the creation of Covid vaccines in 2020, said this week’s cuts made him wonder if he could continue studying pandemics in the United States.

“We’ve had conversations and are beginning to put plans into motion to gather more information,” he said, referring to the possibility of moving abroad.

“My lab is a structural virology lab that focuses on structure-based vaccine design,” he added. “If the focus is on chronic diseases, that doesn’t leave much funding for us.”

Health

Alzheimer’s scientists find key to halting brain decline before symptoms

Published

on

Alzheimer’s scientists find key to halting brain decline before symptoms

NEWYou can now listen to Fox News articles!

Scientists may have found a way to stop Alzheimer’s damage before it starts — by “melting” the tiny protein clumps that are the early triggers of the disease.

Alzheimer’s has long been linked to harmful tau protein fibrils that build up in the brain and interfere with cognitive function, but researchers have now discovered soft, small clusters that appear first.

When those early clusters were dissolved, it prevented the toxic fibrils from forming, which could effectively block the disease, according to researchers from Tokyo Metropolitan University.

HE CARRIES THE ALZHEIMER’S GENE BUT NEVER GOT THE DISEASE — SCIENTISTS WANT TO KNOW WHY

Advertisement

Led by Professor Rei Kurita, the scientists used precise X-ray and fluorescence methods in a laboratory setting to find the microscopic “precursors,” which measured only tens of nanometers, according to a press release.

Because the tiny precursors were soft, the researchers were able to dissolve them. As a result, no tau fibrils were formed.

Scientists may have found a way to stop Alzheimer’s damage before it starts — by “melting” the tiny protein clumps that are the early triggers of the disease. (iStock)

These results suggest a shift in how scientists might develop Alzheimer’s disease treatments.

Rather than focusing on breaking apart the final fibril formations, new therapies could target the earlier, reversible precursor stage to prevent harmful structures from forming in the first place, according to the release.

Advertisement

OMEGA-3 MAY HELP TO PROTECT WOMEN FROM ALZHEIMER’S DISEASE, NEW STUDY SAYS

This strategy could eventually be applied to the research of neurodegenerative diseases like Parkinson’s.

The study did have some limitations, primarily that it involved in-vitro biochemical models and no humans or animals. It’s not known whether similar reversible clusters exist in human brain tissue.

Alzheimer’s has long been linked to harmful tau protein fibrils that build up in the brain and interfere with cognitive function. (iStock)

More research is needed to find out if breaking up these protein clusters is safe and could actually help treat the disease.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Dr. Marc Siegel, Fox News senior medical analyst, was not involved in the study but shared his reactions to the findings.

“There are three essential components structurally involved in the development of Alzheimer’s disease — beta amyloid proteins, tau proteins and neuroinflammation,” he told Fox News Digital.

“In the future, there will likely be triple therapy — anti-inflammation, anti-beta-amyloid and anti-tau.”

“There are already treatments on the market to target beta amyloid buildup, and now here’s a targeted therapy to dissolve and disrupt tau protein buildup before it forms the dreaded neurofibrillatory tangles.”

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Siegel believes this is “bound to be of clinical value” and will likely be better tolerated than other medications currently on the market.

“In the future, there will likely be triple therapy — anti-inflammation, anti-beta-amyloid and anti-tau,” he predicts.

“This is promising basic research that may turn out to deepen our understanding of the mechanisms underlying the disease, but it is preliminary,” an expert said. (iStock)

Courtney Kloske, Ph.D., director of scientific engagement for the Alzheimer’s Association in Chicago, also reacted to the study in an interview with Fox News Digital.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“This manuscript focuses on altering the structure of tau, one of the hallmark brain proteins involved in Alzheimer’s, and on exploring approaches that could potentially slow or stop disease development,” said Kloske, who was also not involved in the study.

CLICK HERE FOR MORE HEALTH STORIES

“This is promising basic research that may turn out to deepen our understanding of the mechanisms underlying the disease, but it is preliminary, and additional studies are needed to determine how these findings can be translated into human studies.”

Fox News Digital reached out to the researchers for comment.

Advertisement

Continue Reading

Health

I’m a Dietitian—Here’s the Best Snack for Weight Loss After 50

Published

on

I’m a Dietitian—Here’s the Best Snack for Weight Loss After 50


Advertisement


I’m a Dietitian—Here’s the Best Healthy Snack for Weight Loss After 50 | Woman’s World




















Advertisement











Advertisement




Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Gut imbalance may be driving America’s food allergy epidemic, experts warn

Published

on

Gut imbalance may be driving America’s food allergy epidemic, experts warn

NEWYou can now listen to Fox News articles!

With over 32 million Americans battling food allergies, health advocates and officials are looking for the root cause — which includes looking into microbiomes.

The Food Allergy Fund (FAF) hosted a forum on Monday in Washington, D.C., with HHS Secretary Robert F. Kennedy, FDA Chief Martin Makary and NIH Director Jay Bhattacharya.

In an interview with Fox News Digital, Makary shared how the function of microbiomes has evolved over time.

EATING BLUEBERRIES EARLIER IN LIFE COULD EASE ALLERGIES, STRENGTHEN IMMUNITY, NEW STUDY FINDS

Advertisement

The intestine hosts over a billion different types of bacteria, which normally live in balance, according to Makary.

The doctor added, “but when it’s altered by the modern-day diet and by antibiotics and other exposures … that disequilibrium can cause inflammation, it can cause health problems, and it may be implicated in food allergies.”

“Gut health is central to overall health,” said Makary, pictured at a Nov. 16 forum hosted by the Food Allergy Fund. (Ashley J. DiMella/Fox News Digital)

“Gut health is central to overall health,” Makary emphasized. Some beneficial microbes may be missing in modern populations due to dietary and environmental changes, which could play a role in the rise of food allergies, he added.

Researchers at Siolta Therapeutics are testing this theory. Their oral microbiome therapy, STMC-103H, has shown promising results in a Phase 2 trial involving 238 newborns with a family history of allergies.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Early data suggests the therapy could reduce the risk of developing food allergies by 77%, indicating that improving gut bacteria early in life could prevent allergies before they start.

Final results are expected in early 2026.

Early data suggests the therapy could reduce the risk of developing food allergies by 77%, indicating that improving gut bacteria early in life could prevent allergies before they start. (iStock)

Ilana Golant, FAF founder and CEO, told Fox News Digital “food allergies may be the canary in the coal mine for a much larger health crisis tied to the microbiome.”

Advertisement

FAF launched its Food Allergy Fund Microbiome Collective in New York City to further investigate how gut bacteria could help prevent or treat not only allergies, but also autoimmune and neurodegenerative diseases.

“Gut health is central to overall health.”

“Solving allergies could reveal how to prevent and treat a range of diseases — from autoimmune disorders to neurodegeneration — that impact millions of lives,” said Golant.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Food allergies are widespread, affecting one in 10 adults and one in 13 children, according to FAF. Every three minutes, someone in the U.S. is treated in the emergency room for a severe allergic reaction.

Advertisement

Peanut allergies are among the most prevalent food allergies in the U.S., with new research showing that early peanut introduction could significantly reduce childhood allergies.

Ilana Golant, FAF founder and CEO (left), chats with HHS Secretary Robert F. Kennedy Jr. in Washington, D.C., at the Food Allergy Fund Forum. (Ashley J. DiMella/Fox News Digital)

Secretary Kennedy observed at the FAF conference that food allergies — particularly involving peanuts — appear to be far more common among children today than when he was growing up.

“When I was a kid, I never met anyone with a peanut allergy,” Kennedy said. “I had 11 siblings and about 71 first cousins, and I didn’t know a single person in my schools or at any of the camps I went to who had one.”

“There may be many causes, or there may be just one — we don’t know yet.”

Advertisement

One of his sons has severe anaphylactic allergies to peanuts, tree nuts and several other foods, he shared. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“By the time he was 2 years old, we’d been to the emergency room about 22 times,” Kennedy said.

“At first, I focused on how we were going to treat it and keep him safe. But my mind quickly went to the bigger question — why is this happening? I have five of my seven children with allergies,” he said.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“There may be many causes, or there may be just one — we don’t know yet,” Kennedy continued. “But we’re going to study it. We’re going to break that omertà, end the taboo and find out what’s causing it.”

Continue Reading

Trending